Innova Captab Ltd. IPO

Innova Captab Limited, a pharmaceutical powerhouse in India, weaves together research, manufacturing, and market reach across domestic and international landscapes. They cater to diverse needs through their three core strengths: a top-ranking CDMO service for Indian pharma companies, a growing portfolio of branded generics marketed in India, and an expanding international presence with exports to 20 countries. Fueled by a strong R&D engine and state-of-the-art facilities, Innova Captab is poised for continued growth, forging a path towards a healthier future for patients worldwide.

RHP
View
DRHP
View
Open Date

2023-12-21

Close Date

2023-12-26

Company Financials

You can get the following financial statements of Innova Captab Ltd. as of now.

The details about the Innova Captab Limited IPO is as:

  • The issue size of the IPO is 570 Cr.
  • The price band for Innova Captab Limited IPO is Rs 426 to Rs 448.
  • The shares of Innova Captab Limited IPO will list on 29th December 2023.
  • The latest tentative GMP of Innova Captab Limited IPO is Rs 110.
  • The shares of Innova Captab Limited IPO is subscribed 55.26 Times as of 26th December 2023. 

 

Innova Captab Limited IPO Valuation

The approx valuation of Innova Captab Limited IPO based on its price band and DRHP (prospectus) is:

Particulars Value
Upper Price Band Rs 448
Existing Shares (Qty) 5.00 Cr
Fresh Issue 320 Cr
Market Cap 2560 Cr
EPS (FY23) Rs 14.16
PE Ratio 31.63x
Industry PE 32.17x

 

Innova Captab Limited IPO Issue Size

Innova Captab Limited IPO issue size is 570 Cr

Issue Amount
Fresh Issue 320 Cr
Offer For Sale 250 Cr

 

Innova Captab Limited IPO Market Lot

An Individual can apply for a minimum 1 lot of 33 shares and a maximum of 13 lots of 429 shares. Find the details below:

Application Lot Shares Amount
 Minimum  1 33 14,784
 Maximum 13 429 1,92,192

 

Innova Captab Limited IPO share offer

The shares of Innova Captab Limited IPO is subscribed 55.26 Times as of 26th December 2023. The category-wise shares offered are as follows:

Category % Offered Subscription
Qualified Institutional Maximum 50% 116.73 Times
Non-Institutional Minimum 15% 64.95 Times
Retail Individual Minimum 35% 17.15 Times
Total   55.26 Times

Find below the dates for Innova Captab Limited IPO:

Schedule Date
Basis of Allotment 27 December 2023
Refunds 27 December 2023
Credit to Demat Account 27 December 2023
IPO Listing Date 29 December 2023

 

Innova Captab Limited IPO allotment is released. Check by clicking on the button below.

Check allotment status

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 373.32 410.66 785.46 858.67 864.93
Total Expenditure 322.39 356.18 686.95 760.14 756.96
Operating Profit 50.93 54.49 98.51 98.53 107.97
Other Income 1.3 1.37 2.86 8.73 10.72
Interest 4.63 3.93 5.33 18.3 13.59
Depreciation 10.08 5.59 7.4 10.66 11.4
Exceptional Items 0 0 0 0 0
Profit Before Tax 37.53 46.34 88.63 78.31 93.7
Provision for Tax 9.64 11.84 22.46 20.76 25.54
Net Profit 27.87 34.42 66.01 57.55 68.16
Adjusted EPS (Rs.) 0.58 0.72 1.38 1.2 1.19

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12 12 12 48 57.23
Total Reserves 98.35 132.82 198.83 220.32 666.49
Borrowings 11.61 6 67.35 134.18 208.2
Other N/C liabilities 2.81 3.64 16.74 57.31 9.75
Current liabilities 129.36 215.15 261.56 259.32 237.97
Total Liabilities 254.13 369.62 556.49 719.13 1179.64
Assets
Net Block 73.16 79.14 161.21 161.37 163.56
Capital WIP 0 7.26 0.03 21.54 338.98
Intangible WIP 0 0 0 0 0
Investments 0 0 60 60 60
Loans & Advances 0.85 12.75 21.69 97.58 154.9
Other N/C Assets 0 0 0.28 0.26 0.2
Current Assets 180.13 270.46 313.28 378.38 462.01
Total Assets 254.13 369.62 556.49 719.13 1179.64
* Other Non-current Liabilities include Net deferred Liabilities

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Other Income 2.11 1.77 6.01 4.64 4.28
Profit Before Tax 20.38 25.51 26.35 29.95 34.32
Tax 5.91 6.86 6.63 7.61 8.71
Profit After Tax 14.47 18.65 19.72 22.34 25.61
Adjusted EPS (Rs) 3.02 3.26 3.45 3.9 4.47

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 50.9 0
Jun 2024 50.9 0
Mar 2024 50.9 0
Dec 2023 50.9 0
Sep 2023 50.9 0
* Figures given above are % of equity capital

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 37.53 46.34 88.63 78.31 93.7
Adjustment 14.46 9.59 12.41 23.58 22.31
Changes in Assets & Liabilities -11.99 -1.14 -21.87 -43.7 19.65
Tax Paid -9.2 -13.23 -20.84 -18.91 -23.99
Operating Cash Flow 30.8 41.56 58.34 39.28 111.67
Investing Cash Flow -6.04 -19.67 -188.33 -87.53 -471.55
Financing Cash Flow -23.28 -19.34 125.3 51.29 368.13
Net Cash Flow 1.48 2.56 -4.69 3.03 8.25

Innova Captab: A Multifaceted Pharmaceutical Powerhouse

Innova Captab Limited is a leading integrated pharmaceutical company in India, spanning the entire pharmaceutical value chain from research and development to manufacturing, distribution, and marketing. They excel in three key areas:

  • Contract Development and Manufacturing Organization (CDMO): Innova Captab provides high-quality manufacturing services to Indian pharmaceutical companies, ranking among the top CDMO players in the country. Their diverse portfolio covers over 600 generic products, catering to a wide range of therapeutic areas.
  • Domestic Branded Generics: Innova Captab leverages its strong in-house R&D to develop and market its own generic medicines in India. Their extensive network of distributors and retailers ensures widespread availability across the country.
  • International Branded Generics: Innova Captab is actively expanding its reach by exporting branded generic products to emerging and semi-regulated markets. They are also making inroads into regulated markets like the UK and Canada.

Key Highlights:

  • Rapid Growth: Innova Captab's revenue has soared at a 50.19% CAGR over the past three years, showcasing their impressive growth trajectory.
  • Strong R&D Foundation: Their dedicated R&D facilities fuel innovation and product development, attracting CDMO clients and bolstering their branded generic portfolio.
  • Manufacturing Expertise: Two state-of-the-art facilities in India, with a third planned, ensure efficient and high-quality production.
  • Diverse Product Portfolio: Over 600 generic products across various therapeutic areas cater to diverse patient needs.
  • Global Reach: Exports to 20 countries and a growing presence in regulated markets like the UK and Canada demonstrate their international ambition.

Innova Captab is a comprehensive pharmaceutical powerhouse poised for continued success. Their commitment to innovation, manufacturing excellence, and diverse product offerings makes them a valuable partner in the Indian and global pharmaceutical landscapes.

Read More
X